KIMS - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | KIMS | Market Cap | 30,373 Cr. | Current Price | 760 ₹ | High / Low | 798 ₹ |
| Stock P/E | 114 | Book Value | 60.7 ₹ | Dividend Yield | 0.00 % | ROCE | 12.8 % |
| ROE | 11.6 % | Face Value | 2.00 ₹ | DMA 50 | 698 ₹ | DMA 200 | 673 ₹ |
| Chg in FII Hold | 0.24 % | Chg in DII Hold | -0.22 % | PAT Qtr | 70.9 Cr. | PAT Prev Qtr | 72.5 Cr. |
| RSI | 61.1 | MACD | 24.7 | Volume | 1,90,865 | Avg Vol 1Wk | 5,61,615 |
| Low price | 576 ₹ | High price | 798 ₹ | PEG Ratio | 62.4 | Debt to equity | 0.63 |
| 52w Index | 82.6 % | Qtr Profit Var | -16.8 % | EPS | 6.52 ₹ | Industry PE | 48.6 |
📊 Financials: KIMS shows moderate fundamentals with ROCE at 12.8% and ROE at 11.6%, reflecting average capital efficiency. Debt-to-equity ratio of 0.63 indicates moderate leverage. EPS stands at ₹6.52, though PAT declined from ₹72.5 Cr. to ₹70.9 Cr., highlighting short-term earnings pressure. Dividend yield at 0.00% offers no direct shareholder returns.
💹 Valuation: Current P/E of 114 is significantly higher than the industry average of 48.6, suggesting extreme overvaluation. P/B ratio (~12.5, 760/60.7) reflects heavy premium pricing relative to book value. PEG ratio of 62.4 indicates growth is severely overpriced. Intrinsic value analysis suggests the stock is richly valued with minimal margin of safety.
🏢 Business Model & Health: KIMS operates in healthcare and hospital services, with competitive advantage in regional presence and specialized medical care. Moderate debt and consistent profitability support sustainability, but weak EPS and high valuations limit attractiveness. Institutional participation is mixed, with FII holdings increasing (+0.24%) but DII holdings declining (-0.22%).
📈 Entry Zone: Technical indicators (RSI 61.1, MACD 24.7, DMA 50 at ₹698, DMA 200 at ₹673) suggest bullish momentum but valuations remain stretched. Accumulation near ₹700–₹740 could be favorable for cautious investors. Long-term holding requires monitoring of earnings growth and valuation risks.
Positive
- ✅ ROCE (12.8%) and ROE (11.6%) reflect moderate capital efficiency.
- ✅ PAT growth resilience despite short-term decline.
- ✅ FII holdings increased (+0.24%), showing foreign investor confidence.
- ✅ Strong presence in healthcare sector with specialized services.
Limitation
- ⚠️ Very high P/E (114) compared to industry average (48.6) suggests extreme overvaluation.
- ⚠️ PEG ratio (62.4) indicates growth is overpriced.
- ⚠️ P/B ratio (~12.5) reflects significant premium pricing.
- ⚠️ Dividend yield (0.00%) offers no shareholder returns.
Company Negative News
- 📉 PAT declined from ₹72.5 Cr. to ₹70.9 Cr., showing earnings pressure.
- 📉 DII holdings declined (-0.22%), signaling reduced domestic institutional confidence.
Company Positive News
- 📈 FII holding increased (+0.24%), reflecting foreign institutional support.
- 📈 Strong sectoral positioning in healthcare services.
Industry
- 🌐 Industry P/E at 48.6 indicates premium sector valuations.
- 🌐 Healthcare sector benefits from rising demand for medical services and infrastructure expansion.
Conclusion
🔎 KIMS is fundamentally stable with moderate returns and strong sectoral positioning, but valuations are extremely stretched with high P/E and PEG ratios. Entry near ₹700–₹740 offers a cautious risk-reward opportunity. Long-term holding is justified only for investors confident in healthcare sector growth, while closely monitoring earnings consistency and valuation risks.